ARTICLE | Company News
Amgen, J&J hematology news
October 28, 2002 8:00 AM UTC
An arbitrator ruled that JNJ breached its epoetin licensing deal with AMGN but allowed the license to continue. AMGN said it was awarded $150 million in damages. The arbitration relates to a 1995 deal...